BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice